Navigation Links
YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB COLORECTAL CANCER TRIAL FIRST COHORT IS CLOSED TO ACCRUAL
Date:12/20/2007

MISSISSAUGA, ON, Dec. 20 /PRNewswire-FirstCall/ - YM BioSciences Inc. (AMEX: YMI, TSX: YM, AIM: YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that it has completed accrual in the first 50-patient cohort of its Phase II trial of nimotuzumab in combination with irinotecan for the treatment of colorectal cancer. The safety profile in the trial to date is consistent with data from previous trials of nimotuzumab, a humanized monoclonal antibody targeting the epidermal growth factor receptor (EGFR), in that there has been no evidence of the severe side effects frequently seen with currently approved EGFR-targeting antibodies and small molecules.

"We are pleased by the enthusiasm of the investigators that resulted in rapid enrollment of this patient cohort and look forward to results from this trial which could provide the evidence to advance nimotuzumab's further development in one of the largest cancer patient populations," said David Allan, Chairman and CEO of YM BioSciences. "Preliminary data on disease control rates should be available toward the end of the first calendar quarter of 2008. Since progression-free survival (PFS) in this patient population historically approximates four months initial observations of nimotuzumab's effect on PFS could be available shortly after the response data."

The single-arm trial in Canada is currently designed to enroll 100 patients in two 50-patient cohorts, consecutively, with the first cohort receiving irinotecan and weekly dosing of nimotuzumab and the second cohort receiving irinotecan with nimotuzumab every two weeks. The endpoints of the trial include the rate and duration of disease control (Stabl
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)...e their cell phones and other personal electronics...e by UC San Diego engineers could lead to carbon n...his. , In recent research, published in Applie... in the UCSD Department of Mechanical and Aerospac...efer, have found that artificially introduced defe...
(Date:11/19/2009)...Call/ -- NeoStem, Inc. (NYSE Amex: NBS ), announc...its shareholders, discussing the Company,s acquisi...cals Holdings, Inc. (CHBP), an integrated bio-phar...of China. The merger gives NeoStem a controlling 5..., CHBP,s primary operating subsidiary and a promin...
(Date:11/19/2009)...nd recognized refractive and cataract surgery expe...their fellow surgeons up-to-date on the latest dev...urgery, and ophthalmology in general at the recent...O) annual meeting in San Francisco, California. Dr... Huang, MD, Dr. Randy Epstein, Dr. William Trattle...
(Date:11/18/2009)...ards and Technology (NIST) has demonstrated a rela...d measuring elusive hazards such as concealed expl...esticides distributed in soil by wind and rain. Th...onal techniques for detecting traces of these mate... distinct electrically positive and negative endsa...
Breaking Biology Technology:Nanotube defects equal better energy and storage systems 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 3Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 2Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 3Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 4Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 5Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 6Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 7Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 8Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 9Prototype NIST method detects and measures elusive hazards 2
.... 14 EntreMed, Inc.,(Nasdaq: ENMD ) a clinical-s...s for the treatment of cancer and inflammatory dis...nt and Chief Executive Officer,will present a Corp...nual,Growth Conference, to be held at the St. Regi...-20, 2007. Mr. Burns, presentation is scheduled fo...
...s 90-day review period-, SOUTH SAN FRANCISCO, Cal...ay announced that the company has,submitted a comp...ithKline,(GSK). As announced in August 2007, GSK r...e compound reaches proof-of-concept as defined und...greement between the two,companies. GSK now has 90...
... Calif., Sept. 13 VaxGen,Inc. (Pink Sheets: VXGN)...sistent with its continuing commitment to align it...tiatives. (Logo: http://www.newscom.com/cgi-bin/... workforce from 61 to 27 employees, which the,comp...es used in operating,activities to $1.4 million. T...
Other Biology Technology:EntreMed to Present at ThinkEquity Partners' 5th Annual Growth Conference 2Exelixis Submits XL880 Diligence Report to GlaxoSmithKline 2VaxGen Further Restructures to Preserve Cash as It Pursues Strategic Initiatives 2
(Date:11/20/2009)... , In the current online issue of the Journa... and Dr. Kilian Eyerich together with their collea...mopatico dell,Immacolata in Rome, present their gr...on the way to developing new treatment methods for...allergic reactions and potentially also allergic r...
(Date:11/20/2009)...hers report that a class of heart medications call...ffect on the heart, depending on their molecular a...al Circulation Research , found that beta-blocker...n the heart muscle offer the most benefit to cardi...-receptors can actually undermine the structure an...
(Date:11/19/2009)...ling the genetic instructions inside corn, one of ...e of the most complex sequences of DNA ever analyz...t David Schwartz, who was one of more than 100 aut..."The maize genome is a true maze full of confusin...e sequencers for years," says Schwartz. , Public...
Breaking Biology News(10 mins):Discovery of new type of immune cells regulating inflammation in chronic diseases 2Carvedilol shown to have unique characteristics among beta blockers 2Sweet corn story begins in UW-Madison lab 2Sweet corn story begins in UW-Madison lab 3State Launches New Campaign to Help Pregnant Smokers Go Tobacco Free 49623 1State Launches New Campaign to Help Pregnant Smokers Go Tobacco Free 49623 2Redesigned Corporate Identity and nowEDC Software Upgrade Reflect Datatrials Commitment To Stress Free Study Delivery 49620 1Redesigned Corporate Identity and nowEDC Software Upgrade Reflect Datatrials Commitment To Stress Free Study Delivery 49620 2Redesigned Corporate Identity and nowEDC Software Upgrade Reflect Datatrials Commitment To Stress Free Study Delivery 49620 3BRAHMS Cezanne and Lumiphore Announce Partnership for Diagnostic Tests 12727 1BRAHMS Cezanne and Lumiphore Announce Partnership for Diagnostic Tests 12727 2BRAHMS Cezanne and Lumiphore Announce Partnership for Diagnostic Tests 12727 3
...ug. 28 Gamma globulin, a type of antibody isolate...en to health care workers and international travel... highly effective treatment for pinkeye with littl...rchers at the University of Pittsburgh School of M... in the September 1 issue of the journal Investiga...
...ncer is one of the most prevalent cancers in the W...then turns into an invasive and violent cancer, wh...ntly published in the journal Cancer Research, Pro...ann Institutes Molecular Cell Biology Department r.... , In a majority of cases, colorectal cancer is ...
...Pennsylvania researchers have designed a nanoscale...s react to external forces. , , By combining mic...hnology to create independent, nanoscale sensors, ...ces and demonstrated a dynamic biological relation...study also revealed that cells sense force at a si...
Other Biology News:Gamma globulin effective in treating eye infections caused by adenoviruses 2A gene for metastasis 2Bioengineers at University of Pennsylvania devise nanoscale system to measure cellular forces 2
29.5" 18" Dedicated Platform with (61) 125ml Clips, for Stackable Shakers from Thermo Scientific
...ne high durability and performance with class-lead... patented triple-counterbalanced heavy-duty mechan...ith heavy out-of-balance loads. The patented HEPA...vy stainless steel interior has coved corners and ...
Cellject Uno 220V includes instruction manual, optimization guide and 10 cuvettes (5 2 mm and 5 4 mm) from Thermo Scientific
Mouse Anti-Bovine GTP BINDING PROTEIN Monoclonal Antibody, Unconjugated, Clone 1H6 from AbD Serotec
Biology Products: